Overview

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Status:
Withdrawn
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as melphalan hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Phase:
Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Melphalan